<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169076</url>
  </required_header>
  <id_info>
    <org_study_id>14.0338</org_study_id>
    <nct_id>NCT02169076</nct_id>
  </id_info>
  <brief_title>Impact of Cardiac Resynchronization Therapy on Right Ventricular Function in Left Ventricular Assist Device Patients</brief_title>
  <acronym>CRT-LVAD</acronym>
  <official_title>Cardiac Resynchronization Therapy in Patients With Left Ventricular Assist Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Left Ventricular Assist Devices (LVAD) are mechanical heart pumps that are increasingly being&#xD;
      implanted in patients with severe heart failure which have failed medical therapy. In&#xD;
      patients with LVADs, right ventricular failure, which is not supported by the LVAD pump, is a&#xD;
      major problem that affects quality-of-life and survival. Cardiac Resynchronization Therapy&#xD;
      (CRT) aims to restore the synchronized contraction of the heart and has proven to be&#xD;
      beneficial for improving ejection fraction of both right and left ventricle as well as&#xD;
      quality of life in selected heart failure patients. The role of CRT in patients with LVADs is&#xD;
      unknown. We hypothesize that CRT can exert a beneficial impact on right ventricular function&#xD;
      in LVAD patients and improve their quality-of-life.&#xD;
&#xD;
      The specific questions that this study aims to answer are:&#xD;
&#xD;
        1. What are the effects of CRT on the function of the non-supported right ventricle in&#xD;
           patients with an implanted LVAD?&#xD;
&#xD;
        2. Can the effects of CRT on cardiac function positively impact quality-of-life and&#xD;
           exercise capacity in LVAD recipients?&#xD;
&#xD;
      In this study patients with a previously implanted CRT device, who later receives an LVAD,&#xD;
      will be randomly assigned to have the CRT turned off (CRT-off) or on (CRT-on). The patients&#xD;
      will be followed for an 8-week period, and then switched over to the opposite CRT status. The&#xD;
      total participation in this study will last for 16 ± 1 weeks, and will involve 3 clinic&#xD;
      visits of approximately 3 hour duration (initial visit, 8 week visit, and 16 week final&#xD;
      visit), plus 2 quick checks of the pacemaker/defibrillator in-between the visits. Heart&#xD;
      function will be assessed with comprehensive echocardiographic studies during the CRT &quot;on&quot;&#xD;
      and CRT &quot;off&quot; periods. Quality-of-life and exercise capacity will be assessed with a&#xD;
      standardized questionnaire and a 6-Minute Walk Test.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IRB Approval withdrawn&#xD;
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right ventricular function</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary cardiac performance endpoint is global longitudinal right ventricular (RV) function assessed by myocardial strain analysis using Speckle Tracking Echocardiography (STE).&#xD;
Other traditional echocardiographic RV function indexes will also be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional capacity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Will be assessed by 6-Minute Walk Test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality-of-Life</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed by standardized self administered Minnesota Living with Heart Failure Questionnaire (MLHFQ)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CRT-On</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cardiac Resynchronization Therapy enabled on ICD/Pacemaker device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRT-Off</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Cardiac Resynchronization Therapy disabled on ICD/Pacemaker device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac Resynchronization Therapy</intervention_name>
    <description>The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.</description>
    <arm_group_label>CRT-Off</arm_group_label>
    <arm_group_label>CRT-On</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Heart failure patients with previously implanted Bi-Ventricular pacemaker /&#xD;
             defibrillator, and continuous flow LVAD (Heart Mate II® or HeartWare®)&#xD;
&#xD;
          -  The LVAD must be implanted between 8 weeks and 18 months prior to enrollment&#xD;
&#xD;
          -  Patients should be at least 3 weeks post discharge from the LVAD implant&#xD;
             hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe decompensated right ventricular failure defined as requiring any of the&#xD;
             following:&#xD;
&#xD;
               -  Hospitalization for heart failure within last 30 days&#xD;
&#xD;
               -  Need for inotropic infusion for &gt; 48h within the last 14 days&#xD;
&#xD;
               -  Increase of &gt; 100% diuretic dose within last 14 days&#xD;
&#xD;
          -  Severe aortic regurgitation documented by echocardiography or cardiac catheterization&#xD;
&#xD;
          -  Stage IV or greater kidney disease (GFR &lt; 30 mL/min/1.73 m2)&#xD;
&#xD;
          -  Active infection (not including controlled chronic driveline infection on suppressive&#xD;
             antibiotic therapy)&#xD;
&#xD;
          -  Biventricular pacing &lt; 90 % of time due to uncontrolled arrhythmias&#xD;
&#xD;
          -  LVAD malfunction&#xD;
&#xD;
          -  Inability to follow study protocol&#xD;
&#xD;
          -  Non-functional LV lead (i.e. high capture threshold that cannot be corrected with&#xD;
             programming changes)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rakesh Gopinathannair, MD, MA, FHRS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin A Espinosa Ginic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventricular Assist Device, Cardiac Resynchronization Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

